Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Ventilation
ICU
Serious outcomes
Recovery
Cases
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Budesonide  COVID-19 treatment studies for Budesonide  C19 studies: Budesonide  Budesonide   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 budesonide studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 45% 3 8,751 Improvement, Studies, Patients Relative Risk, 95% CI Mortality 39% 1 1,586 Ventilation 6% 1 1,560 ICU admission 52% 1 1,550 Recovery 43% 2 1,995 Cases 33% 1 7,019 RCTs 62% 2 1,732 Peer-reviewed 62% 2 1,732 Prophylaxis 33% 1 7,019 Early 82% 1 146 Late 39% 1 1,586 Budesonide for COVID-19 c19budesonide.com Dec 7, 2021 Favors budesonide Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ramakrishnan (RCT) 82% 0.18 [0.04-0.79] hosp./ER 2/73 11/73 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 82% 0.18 [0.04-0.79] 2/73 11/73 82% improvement Yu (RCT) 39% 0.61 [0.22-1.67] death 6/787 10/799 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 39% 0.61 [0.22-1.67] 6/787 10/799 39% improvement Lee 33% 0.67 [0.42-1.08] cases 19/1,674 95/5,345 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 33% 0.67 [0.42-1.08] 19/1,674 95/5,345 33% improvement All studies 45% 0.55 [0.31-0.98] 27/2,534 116/6,217 45% improvement 3 budesonide COVID-19 studies c19budesonide.com Dec 7, 2021 Tau​2 = 0.08; I​2 = 27.1%; Z = 2.01 Effect extraction pre-specified Favors budesonide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Yu (RCT) 39% 0.61 [0.22-1.67] 6/787 10/799 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 39% 0.61 [0.22-1.67] 6/787 10/799 39% improvement All studies 39% 0.61 [0.22-1.67] 6/787 10/799 39% improvement 1 budesonide COVID-19 mortality result c19budesonide.com Dec 7, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 0.96 Favors budesonide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Yu (RCT) 6% 0.94 [0.44-1.98] 13/776 14/784 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 6% 0.94 [0.44-1.98] 13/776 14/784 6% improvement All studies 6% 0.94 [0.44-1.99] 13/776 14/784 6% improvement 1 budesonide COVID-19 mechanical ventilation result c19budesonide.com Dec 7, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 0.16 Favors budesonide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Yu (RCT) 52% 0.48 [0.23-1.01] 10/771 21/779 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 52% 0.48 [0.23-1.01] 10/771 21/779 52% improvement All studies 52% 0.48 [0.23-1.01] 10/771 21/779 52% improvement 1 budesonide COVID-19 ICU result c19budesonide.com Dec 7, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 1.93 Favors budesonide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ramakrishnan (RCT) 82% 0.18 [0.04-0.79] hosp./ER 2/73 11/73 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 82% 0.18 [0.04-0.79] 2/73 11/73 82% improvement Yu (RCT) 39% 0.61 [0.22-1.67] death 6/787 10/799 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 39% 0.61 [0.22-1.67] 6/787 10/799 39% improvement All studies 62% 0.38 [0.12-1.20] 8/860 21/872 62% improvement 2 budesonide COVID-19 serious outcomes c19budesonide.com Dec 7, 2021 Tau​2 = 0.32; I​2 = 43.4%; Z = 1.65 Effect extraction pre-specified Favors budesonide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ramakrishnan (RCT) 67% 0.33 [0.15-0.72] no recov. 7/70 21/69 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 67% 0.33 [0.15-0.72] 7/70 21/69 67% improvement Yu (RCT) 17% 0.83 [0.74-0.93] recov. time 787 (n) 1,069 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 17% 0.83 [0.74-0.93] 0/787 0/1,069 17% improvement All studies 43% 0.57 [0.23-1.38] 7/857 21/1,138 43% improvement 2 budesonide COVID-19 recovery results c19budesonide.com Dec 7, 2021 Tau​2 = 0.34; I​2 = 80.6%; Z = 1.25 Favors budesonide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lee 33% 0.67 [0.42-1.08] 19/1,674 95/5,345 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 33% 0.67 [0.42-1.08] 19/1,674 95/5,345 33% improvement All studies 33% 0.67 [0.41-1.10] 19/1,674 95/5,345 33% improvement 1 budesonide COVID-19 case result c19budesonide.com Dec 7, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 1.58 Favors budesonide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ramakrishnan (RCT) 82% 0.18 [0.04-0.79] hosp./ER 2/73 11/73 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 82% 0.18 [0.04-0.79] 2/73 11/73 82% improvement Yu (RCT) 39% 0.61 [0.22-1.67] death 6/787 10/799 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 39% 0.61 [0.22-1.67] 6/787 10/799 39% improvement All studies 62% 0.38 [0.12-1.20] 8/860 21/872 62% improvement 2 budesonide COVID-19 Randomized Controlled Trials c19budesonide.com Dec 7, 2021 Tau​2 = 0.32; I​2 = 43.4%; Z = 1.65 Effect extraction pre-specified Favors budesonide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Yu (RCT) 39% 0.61 [0.22-1.67] 6/787 10/799 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 39% 0.61 [0.22-1.67] 6/787 10/799 39% improvement All studies 39% 0.61 [0.22-1.67] 6/787 10/799 39% improvement 1 budesonide COVID-19 RCT mortality result c19budesonide.com Dec 7, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 0.96 Favors budesonide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ramakrishnan (RCT) 82% 0.18 [0.04-0.79] hosp./ER 2/73 11/73 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 82% 0.18 [0.04-0.79] 2/73 11/73 82% improvement Yu (RCT) 39% 0.61 [0.22-1.67] death 6/787 10/799 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 39% 0.61 [0.22-1.67] 6/787 10/799 39% improvement All studies 62% 0.38 [0.12-1.20] 8/860 21/872 62% improvement 2 budesonide COVID-19 peer reviewed trials c19budesonide.com Dec 7, 2021 Tau​2 = 0.32; I​2 = 43.4%; Z = 1.65 Effect extraction pre-specified Favors budesonide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ramakrishnan (RCT) 82% 0.18 [0.04-0.79] hosp./ER 2/73 11/73 Improvement, RR [CI] Treatment Control Ramakrishnan (RCT) 90% 0.10 [0.01-0.75] hosp./ER 1/70 10/69 Ramakrishnan (RCT) 67% 0.33 [0.15-0.72] no recov. 7/70 21/69 Yu (RCT) 39% 0.61 [0.22-1.67] death 6/787 10/799 Yu (RCT) 6% 0.94 [0.44-1.98] ventilation 13/776 14/784 Yu (RCT) 52% 0.48 [0.23-1.01] ICU 10/771 21/779 Yu (RCT) 25% 0.75 [0.55-1.03] hosp./death 72/787 116/1,069 Yu (RCT) 17% 0.83 [0.74-0.93] recov. time 787 (n) 1,069 (n) Lee 33% 0.67 [0.42-1.08] cases 19/1,674 95/5,345 budesonide COVID-19 outcomes c19budesonide.com Dec 7, 2021 Favors budesonide Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit